If you suffered a loss as a result of AxoGen’s misconduct, click here.
AxoGen, Inc. (AXGN) Accused of Grossly Overcompensating its Directors
According to the derivative complaint, between
AxoGen, Inc. (AXGN) Shareholders Have Legal Options
Contact us to learn more:
LKandinov@robbinsarroyo.com
Shareholder Information Form
View source version on businesswire.com: https://www.businesswire.com/news/home/20190814005649/en/
LKandinov@robbinsarroyo.com
(619) 525-3990 or Toll Free (800) 350-6003
www.robbinsarroyo.com
Source:
Philly gene-therapy firm based on Temple University research raises $11 million
US Consumer Prices Rose 0.3% Amid Widespread Cost Increases
More Articles